Quarterly report [Sections 13 or 15(d)]

LICENSES ACQUIRED (Details)

v3.26.3
LICENSES ACQUIRED (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Nov. 11, 2024
Jun. 29, 2021
Dec. 31, 2024
Apr. 30, 2024
Jan. 31, 2022
Mar. 31, 2021
Jul. 31, 2020
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Assets and Licenses Acquired                      
Total other revenues               $ 42 $ 606 $ 753 $ 606
Amzeeq                      
Assets and Licenses Acquired                      
Percentage of license         4.00%            
Zilxi                      
Assets and Licenses Acquired                      
Percentage of license         1.50%            
Emrosi Agreement                      
Assets and Licenses Acquired                      
Total Upfront payment   $ 10,000                  
Upfront payment upon execution       $ 3,000              
Remaining upfront payment     $ 15,000                
Transformation of ownership and all assets of milestone payments   15,000                  
Threshold additional contingent regulatory and commercial milestone payments payable   $ 150,000                  
Percentage of reduction in royalty upon launching of competitor products   50.00%                  
Emrosi Agreement | Minimum                      
Assets and Licenses Acquired                      
Percentage of royalties payable on net sales   10.00%                  
Emrosi Agreement | Maximum                      
Assets and Licenses Acquired                      
Percentage of royalties payable on net sales   14.00%                  
Asset purchase agreement | Qbrexza                      
Assets and Licenses Acquired                      
Age of patients           9 years          
Asset purchase agreement | Royalty payment percentage for first two years | Qbrexza                      
Assets and Licenses Acquired                      
Period of royalty payments           2 years          
Asset purchase agreement | Minimum | Royalty payment percentage for first two years | Qbrexza                      
Assets and Licenses Acquired                      
Percent of royalty payments           40.00%          
Asset purchase agreement | Minimum | Royalty payment percentage for thereafter | Qbrexza                      
Assets and Licenses Acquired                      
Percent of royalty payments           12.00%          
Asset purchase agreement | Maximum | Royalty payment percentage for first two years | Qbrexza                      
Assets and Licenses Acquired                      
Percent of royalty payments           30.00%          
Asset purchase agreement | Maximum | Royalty payment percentage for thereafter | Qbrexza                      
Assets and Licenses Acquired                      
Percent of royalty payments           19.00%          
Asset purchase agreement | Eli Lilly and Company | Qbrexza                      
Assets and Licenses Acquired                      
Upfront fees           $ 12,500          
Milestone payments payable           $ 144,000          
License and supply agreement With DRL | Accutane                      
Assets and Licenses Acquired                      
Amount of expense agreed to pay under the agreement             $ 5,000        
Contingent amount payable             $ 17,000        
Term of accutane             10 years        
Termination accutane agreement period             180 days        
Cutia License Agreement | Amzeeq                      
Assets and Licenses Acquired                      
Milestone payment $ 1,000                    
Total other revenues $ 1,000                    
VYNE APA                      
Assets and Licenses Acquired                      
Total Upfront payment         $ 450,000            
Upfront payment upon execution         5,000            
Upfront fees         20,000            
VYNE APA | Amzeeq | First year anniversary                      
Assets and Licenses Acquired                      
Net sales         100,000            
Amount of expense paid under the agreement         10,000            
VYNE APA | Amzeeq | Second year anniversary                      
Assets and Licenses Acquired                      
Net sales         200,000            
Amount of expense paid under the agreement         20,000            
VYNE APA | Amzeeq | Third year anniversary                      
Assets and Licenses Acquired                      
Net sales         300,000            
Amount of expense paid under the agreement         30,000            
VYNE APA | Amzeeq | Fourth year anniversary                      
Assets and Licenses Acquired                      
Net sales         400,000            
Amount of expense paid under the agreement         40,000            
VYNE APA | Amzeeq | Fifth year anniversary                      
Assets and Licenses Acquired                      
Net sales         500,000            
Amount of expense paid under the agreement         50,000            
VYNE APA | Zilxi | First year anniversary                      
Assets and Licenses Acquired                      
Net sales         100,000            
Amount of expense paid under the agreement         10,000            
VYNE APA | Zilxi | Second year anniversary                      
Assets and Licenses Acquired                      
Net sales         200,000            
Amount of expense paid under the agreement         20,000            
VYNE APA | Zilxi | Third year anniversary                      
Assets and Licenses Acquired                      
Net sales         300,000            
Amount of expense paid under the agreement         30,000            
VYNE APA | Zilxi | Fourth year anniversary                      
Assets and Licenses Acquired                      
Net sales         400,000            
Amount of expense paid under the agreement         40,000            
VYNE APA | Zilxi | Fifth year anniversary                      
Assets and Licenses Acquired                      
Net sales         500,000            
Amount of expense paid under the agreement         $ 50,000